Pages that link to "Item:Q2441853"
From MaRDI portal
The following pages link to Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853):
Displaying 13 items.
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment (Q5051094) (← links)
- Application of gamma process to two-agent combinations with delayed toxicity (Q5083969) (← links)
- BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons (Q5857110) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
- Biomarker-based precision dose finding for immunotherapy combined with radiotherapy (Q6572286) (← links)
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review (Q6577811) (← links)
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials (Q6626759) (← links)
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
- Early completion of phase I cancer clinical trials with Bayesian optimal interval design (Q6628100) (← links)
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
